GLP-1 Receptor Agonists Improve Psoriatic Arthritis Outcomes Beyond Weight Loss

GLP-1 receptor agonists produced clinically meaningful reductions in joint pain, systemic inflammation, and cardiometabolic risk in psoriatic arthritis patients — effects that tracked proportionally with weight loss and may hint at direct immunomodulatory properties.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin-based peptide therapies originally developed for type 2 diabetes and obesity. Growing evidence suggests they also reduce systemic inflammation through mechanisms that may extend beyond weight loss, including direct effects on GLP-1 receptors expressed on immune cells.

Key Findings

Haberman et al. at NYU Grossman School of Medicine conducted a retrospective analysis of two cohorts totaling 48 patients with psoriatic arthritis (PsA) who initiated GLP-1RA therapy, published in Arthritis & Rheumatology.¹

Weight and metabolic outcomes:

• Significant weight loss: −6.43 kg (95% CI: −9.5, −2.0; p < 0.0001)
• 60% of patients achieved ≥5% body weight reduction
• Triglycerides decreased by −0.35 mmol/L (p = 0.02)

Disease activity improvements:

• CRP reduced by −1.1 mg/L (p = 0.002)
• Pain scores decreased by −1.0 point (p = 0.01)
• Each 1% reduction in body weight was associated with:
  • DAPSA improvement: β = −0.49 (95% CI: −0.94, −0.03)
  • Tender joint count reduction: β = −0.18 (95% CI: −0.32, −0.05)
  • Quality of life (EQ-5D) improvement: β = 0.0016 (95% CI: 0.008, 0.023)
  • LDL reduction: β = −0.05 (95% CI: −0.10, −0.003)
  • Systolic blood pressure reduction: β = −0.67 (95% CI: −1.18, −0.15)

Study Context

The median baseline BMI was 34.9, reflecting the high prevalence of obesity in PsA. The study is limited by its retrospective design, small sample size, and lack of a comparator group. However, the consistent dose-response relationship between weight loss and multiple PsA outcomes is notable and aligns with the broader pattern of GLP-1RA benefits in inflammatory conditions identified in previous umbrella reviews.

Why This Matters

This study adds PsA to the growing list of inflammatory conditions — including cardiovascular disease, MASH, and kidney disease — where GLP-1RAs show benefit beyond glucose and weight control. For the estimated 30–45% of PsA patients who are obese, GLP-1RAs could serve a dual purpose: managing weight while potentially improving joint disease activity.

Clinical implication: Rheumatologists managing obese PsA patients already on or considering GLP-1RA therapy for metabolic indications should monitor disease activity scores, as weight loss on these agents may produce meaningful PsA improvements — though randomized trials are needed before recommending GLP-1RAs specifically for PsA management.

---

¹ Haberman RH, Rice AL, Chen K, et al. Glucagon-like peptide-1 receptor agonist therapy is associated with improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts. Arthritis Rheumatol. 2026. doi:10.1002/art.70170